CS-1036 phase 2 study - dose response study of CS-1036 in patients with type 2 diabetes -

Authors
Category Primary study
Registry of TrialsJapan Pharmaceutical Information Center
Year 2010
INTERVENTION: Intervention name : CS‐1036 Dosage And administration of the intervention : Oral CONDITION: Patients with Type 2 Diabetes PRIMARY OUTCOME: Postprandial glucose SECONDARY OUTCOME: 1. plasma glucose, serum insulin, glycoalbumin, 1,5‐anhydroglucitol, HbA1c, and urinary C‐peptide; 2. Safety and tolerability INCLUSION CRITERIA: Patients diagnosed with type 2 diabetes mellitus
Epistemonikos ID: f50f5f4c45dbecb5be0350eb879e0840e069b8d5
First added on: Aug 22, 2024